Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366027 · ClinicalTrials.gov registry record
PRISM Registry: Pseudobulbar Affect Registry Series
A clinical trial, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- 5,290
- Enrollment target
NCT01366027: Completed study, sponsored by Avanir Pharmaceuticals.
NCT01366027 is a clinical trial that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 5,290 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01366027 has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- 5,290 participants
- Enrollment target
Study Summary
PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated. The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including * Alzheimer's disease * Amyotrophic lateral sclerosis * Multiple sclerosis * Parkinson's disease * Stroke * Traumatic brain injury Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.
Primary Outcome
The objective of the registry is to determine the prevalence of pseudobulbar affect (PBA) in patients with certain underlying neurologic conditions: Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD), Stroke (STR), and Traumatic Brain Injury (TBI). Presence of PBA symptoms was defined as CNS-LS score \>=13.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,290 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-09 |
What the finished NCT01366027 record still lists
NCT01366027 is an observational study that tracks outcomes without assigning an intervention. Its 5,290 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01366027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01366027 about?
NCT01366027 is a clinical study titled "PRISM Registry: Pseudobulbar Affect Registry Series". PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress...
What is the current status of trial NCT01366027?
This trial is currently completed. The enrollment target is 5,290 participants. The study started on 2011-05. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT01366027?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia